الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Colon cancer is the third most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide. Several approaches including colonoscopy, evaluation of serum markers as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), together with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans are used to diagnose colon cancer. Thus, it is mandatory to find a noninvasive biomarker that can be employed for early diagnosis, For these aims, blood samples from 96 patients with bowel disease, 22 patients with benign condition and 74 patients with colon cancer in addition, blood samples from age- and sex-matched 32 normal individuals, as a control group were included in the study. For normal individuals, patients with benign and patients with colon cancer, laboratory tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum albumin and creatinine were measured using standard methodologies and also WBCs and platelets counting were determined. In conclusion: EMA antigen was identified using SDS-PAGE followed by western blotting technique at 130-kDa. Quantification of EMA antigen in colon cancer patients by ELISA; the detection rate and concentration of EMA antigen increased with progression of colon cancer.